

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURE

- I. Purpose
 - A. To reduce the risk of infection following exposure to nonhuman primate (NHP) body fluids.
 - B. To utilize information from these injuries to enhance worker safety.
- II. Relevant Occupational Medical Service (OMS) Procedure Manual Sections
 - A. Occupational Injury and Illness. Chapter III Section 20
 - B. Wound Care Guidelines. Chapter III Section 36
 - C. Animal Exposure Program. Chapter IV Section 1
 - D. Retrovirus Exposure. Chapter III Section 28
- III. Attachments
 - A. Information and Specimens Requested following an Exposure to a NHP Body Fluid. Attachment I
 - B. Report of Injury Involving a NHP Body Fluid. Attachment II
 - C. B Virus Backgrounder. Attachment III
 - D. B Virus Wallet Card. Attachment IV
- IV. Background
 - A. The significance of an injury involving NHP body fluid depends, among other things, upon the type of NHP, the body fluid, and the route of exposure. The following is a brief description of some viruses found in NHP body fluids, how they are transmitted to humans and the significance of the resulting infection.
 - B. Rhesus, cynomolgus, pig-tail and stump-tail NHPs and other macaques may be infected with B virus (*Macacine herpesvirus 1*, formerly *Cercopithecine herpesvirus 1*), or simian type D retrovirus serotypes (SRVs). In addition, these NHPs can be experimentally infected with simian/human immunodeficiency virus (SHIV).
 - 1. B virus
 - a. Like herpes simplex virus (HSV) infections in humans, B virus may persist in the NHP's sensory ganglia and be shed periodically in oral, ocular, or genital secretions. Usually viral shedding occurs without any clinical findings. Two percent of NHPs infected with B virus are likely to shed on any given day. This percentage will rise, if the infected NHP's immune system is compromised or if the animal is stressed.
 - b. Transmission to humans has resulted from bites, scratches, and other incidents that expose the worker to NHP's mucous membrane fluids, cerebral spinal fluid, or neurologic tissue. B virus is not transmitted by exposure to blood from an infected

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

- animal.
 - c. HSV may enter sensory nerve endings within five minutes. B virus is thought to infect the same sensory nerve cells just as rapidly.
 - d. The incubation period for human infection ranges from two days to five weeks. Most cases present within three weeks of the exposure. Initial complaints frequently include flu-like symptoms (i.e., fever, myalgias, fatigue and headache) with or without localized findings at the injury site such as herpetic vesicles, pain or tingling. Peripheral or central nervous system manifestations of infection may vary.
 - e. Although human infection with B virus is a very infrequent occurrence, approximately 70% of workers infected with B virus have died from complications of their infections. As a result, appropriate first aid should be administered immediately and consideration should be given to the prompt administration of postexposure prophylaxis.
2. SRV
- a. SRVs, a group of closely related retroviruses, naturally infect rhesus macaques. SRV has been identified as the etiologic agent of an infectious immunodeficiency disease in macaques that resembles infection with human immunodeficiency virus type 1 (HIV-1) in humans. Vaccines are under development to prevent this infection with devastating consequences in captive populations of macaque species.
 - b. SRV is present in blood, saliva, urine and other body fluids.
 - c. The CDC has reported that two of 398 individuals (0.5%) with occupational contact with nonhuman primates had seroreactivity to SRV antigens. The investigators were unable to detect SRV-infected cells by polymerase chain reaction (PCR) testing or to culture the virus. Although SRV replicates in human cells, neither worker has developed symptoms suggestive of an infection with a retrovirus.
3. SHIV
- a. SHIV strains are chimeric viruses that combine genetic sequences from HIV-1 with genes of the simian immunodeficiency virus (SIV). They are designed to study how HIV-1 behaves in animal research models by making the new viral constructs mimic HIV-1 infection more closely than SIV does.
 - b. SHIV can be recovered from the same body fluids and tissues as HIV-1.
 - c. Occupational transmission of SHIV has not yet been reported. As a result, the consequences of infection with SHIV are not yet defined.
- C. African green monkeys, baboons, sooty mangabeys and chimpanzees may be

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

naturally infected with SIV or Simian Foamy Virus (SFV).

1. SIV
 - a. SIV is genetically and antigenically related to HIV-2. Animals naturally infected with SIV typically do not develop immunodeficiency disease. However, when SIV crosses over to infect other NHP species, either experimentally or by accidental exposure of a colony, it may be lethal to susceptible NHPs.
 - b. The virus has been isolated from blood, plasma, cerebrospinal fluid, and parenchymal tissues. Transmission to man may occur following percutaneous and mucous membrane exposures to body fluids containing white blood cells.
 - c. Testing at the CDC has shown that three of 472 individuals (0.6%) with nonhuman primate contact have developed laboratory evidence of infection with SIV. However, the virus could not be cultured in any of these cases. So far, none of these individuals has developed clinical evidence of disease or of immune suppression.
2. SFV
 - a. There is no recognized human analogue retrovirus for SFV and there is no recognized disease state associated with SFV infection in its natural host or in man.
 - b. SFV can be experimentally transmitted by blood transfusions. It is suspected that transmission to workers may be associated with percutaneous wounds such as bites, scratches, and sharps injuries.
 - c. The CDC has reported that 13 of 398 individuals (3.3%) who worked with nonhuman primates have serologic evidence of exposure to SFV. PCR testing was positive from several of these workers and the virus was cultured from two individuals.

- V. Nonhuman primate testing following a reported injury is based upon the type of NHP and body fluid involved in the incident (the rationale for this is outlined in Section IV above and in Attachment I). In addition, the OMS healthcare provider routinely asks whether the NHP has any known natural or experimental infections. If the NHP was used in an experiment with a human pathogen OMS staff may request additional testing.
 - A. Macaque blood. If the incident involves blood from a macaque (e.g., rhesus, cynomolgus, pig-tail, stump-tail monkeys) and there is a possibility that the area could be contaminated with the NHP oral, ocular, or genital fluids the following information and biologic specimens are requested:
 1. A report of physical exam findings including whether or not the NHP has oral or genital vesicles, ulcerations, or crusts, or conjunctivitis.
 2. One virus culture that contains swabs from the macaque's mouth, conjunctival sacs, and genitalia. Special care should be taken to swab all vesicles, ulcerations, or crusts. More than one cotton swab may be placed in the transport media. Cultures should be obtained as soon as

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

- feasible.
- 3. Serum only from animals that have never tested positive for antibodies to B virus.
- B. Macaque saliva. If the incident involves saliva from a macaque, the following information and biologic specimens are requested:
 - 1. A report of physical exam findings including whether or not the NHP has oral or genital vesicles, ulcerations, or crusts, or conjunctivitis.
 - 2. Two virus cultures:
 - a. One from the macaque's mouth, using care to swab any ulcers that might be present.
 - b. The second from the macaque's conjunctival sacs and genitalia. Any vesicles, ulcerations, or crusts should be swabbed. More than one cotton swab may be placed in the transport media. Cultures should be obtained as soon as feasible.
 - 3. Serum only from animals that have never tested positive for antibodies to B virus.
- C. Macaque unidentified body fluid. If the accident involves a potential exposure to an unidentified macaque body fluid by way of a scratch, mucous membrane splash, or injury involving a soiled cage, OMS requests:
 - 1. A report of physical exam findings including whether or not the NHP has oral or genital vesicles, ulcerations, or crusts, or conjunctivitis.
 - 2. One virus culture that contains swabs from the macaque's mouth, conjunctival sacs, and genitalia. Special care should be taken to swab all vesicles, ulcerations, or crusts. More than one cotton swab may be placed in the transport media. Cultures should be obtained as soon as feasible.
 - 3. Serum only from animals that have never tested positive for antibodies to B virus.
- D. African green monkey, baboon, sooty mangabey, or chimpanzee blood. If the incident involves exposure to blood from one of these NHPs by way of a percutaneous injury or a splash to non-intact skin or mucous membranes, OMS requests serum for SIV testing only from animals that have not previously tested positive for antibodies to SIV.
- E. African green monkey, baboon, sooty mangabey, or chimpanzee saliva or other, unidentified body fluid. If the injury involves potential exposure to a body fluid other than blood, biologic testing is not routinely required.
- F. Marmoset, squirrel, or owl monkey body fluids. Pathogens found in marmosets, squirrel and owl monkeys generally do not constitute a health risk for humans. Routine laboratory testing is not necessary following an exposure to body fluids from these NHPs. The OMS healthcare provider will ask if the animal involved may have been exposed to NHPs of different species to determine any indirect risk to the worker of human pathogen exposure from those NHPs.

VI. Specimen Identification and Handling

- A. Virus cultures use the same transport media as listed in V.D.3.b and specimens

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

are labeled with the following information:

1. The animal's identifying information,
 2. The date the specimen was obtained,
 3. The sites swabbed (e.g., mouth, eyes, genitalia), and
 4. The date that the injury occurred.
- B. Blood must be obtained using a red top plastic tube. The blood should be permitted to sit and clot for 30 minutes before centrifuging. Alternately, for work groups off campus, blood can be obtained in a serum separator tube (SST), to avoid delaying the medical evaluation. Regardless, the label on the tube should include the following information:
1. The animal's identifying information
 2. The date the specimen was obtained.
- C. Virus cultures and blood specimens should be placed on ice and delivered to OMS or refrigerated (4°C) until delivery the next business day. It is important that the swabs remain submerged in the viral medium during storage and/or transport. Specimens should be accompanied with the name, phone number, building and room number of the IC and Facility Veterinarian.

VII. Employee Medical Assessment and Treatment

- A. Reporting. Anyone (e.g., NIH employees, contractors, others) exposed to NHP body fluids in an NIH facility must report to OMS for evaluation and care. During non-clinic hours, workers contact the on-call OMS healthcare provider by calling the NIH page operator on 301-496-1211.
- B. First aid. First aid procedures are outlined in the OMS Wound Care Guidelines.
1. First aid should be performed at the worksite, unless the worker can get to OMS in less than five minutes. Employees working in animal care facilities off campus, frequently call OMS to discuss the medical significance of the injury.
 2. If the employee reports to OMS within eight hours of the incident, first aid is repeated, regardless of whether or not it was performed at the worksite.
- C. Medical assessment. As first aid is being administered, a standardized, targeted medical history is obtained using the Accident Reporting System in the OMS electronic medical record system. The OMS healthcare provider completes a Report of Injury Involving a NHP Body Fluid form (Attachment II) to clarify the circumstances of the injury. The following information is obtained:
1. When the injury occurred.
 2. Safety measures employed at the time of the injury.
 3. Type of injury (e.g., skin or a mucous membrane exposure, percutaneous injury).
 4. Type and amount of fluid contacted.
 5. Circumstances of the accident.
 6. The identity of the nonhuman primate involved in the injury.
 7. Details regarding first aid provided at the work site.
- D. Laboratory Testing

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

1. B virus. If the injury involved a potential percutaneous or mucous membrane exposure to B virus, a virus culture is obtained from the wound following the administration of first aid at OMS. Decisions regarding bacterial cultures are made on a case-by-case basis.
 2. Retroviruses. If the injury involved skin or mucous membrane contact or a percutaneous exposure to blood or another blood contaminated body fluid from a nonhuman primate suspected to be infected with SIV or SHIV, the worker is offered serologic monitoring for infection. The utility of monitoring for conversion after potential exposure to other retroviruses will be determined with each case individually. If postexposure prophylaxis with antiretrovirals is started, baseline testing will include a complete blood count, a chemistry panel, amylase, lipase, and urinalysis.
 3. Laboratory specimens.
 - a. A blood sample is obtained following every suspected injury involving an exposure to NHP body fluids, unless a sample was obtained in the preceding six months. The serum is stored at -20°C for possible future reference.
 - b. The virus culture is obtained using Hank's Buffered Salts Solution (Bartel's Viral Transport Media) and labeled with the employee's name, date the specimen was obtained and that it was from the wound post scrub. Virus cultures obtained after 2 pm on Thursday are stored at -70°C and shipped Monday morning.
- E. Treatment
1. B virus. A worker who sustains a possible percutaneous or mucous membrane exposure to B virus is:
 - a. Counseled regarding the significance of the incident and provided with a B Virus Handout (Attachment III) and a related wallet-sized card (Attachment IV),
 - b. Offered valacyclovir 500 mg, 42 tablets to be taken as two tablets every eight hours, and
 - c. Given an appointment to return to clinic in one week.
 2. Retroviruses. A worker who sustains a suspected percutaneous or mucous membrane exposure to SIV or SHIV is counseled, treated and followed as outlined in the OMS Retrovirus Exposure procedure.
 3. Treatment after hours. If post exposure prophylaxis is indicated during non-clinic hours, the OMS healthcare provider:
 - a. Instructs the worker to go to the CC Pharmacy to obtain the medication,
 - b. Contacts the CC Pharmacy by calling 301-496-2867 and requests that the prescription(s) be labeled as HCW-last four digits of the worker's social security number,
 - c. If the worker is a woman of childbearing capacity and antiretroviral treatment is recommended, offers to perform a pregnancy test in OMS and counsels her appropriately regarding her treatment plan, and

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

- d. If circumstances of the injury dictate arranges to meet with the worker in person in the OMS clinic.
 4. Nurse coordinator. The OMS nurse coordinator for injuries potentially involving NHP body fluids is alerted to all such injuries reported to OMS. The coordinator tracks all related laboratory test results and employee compliance with follow-up appointments.
- F. Follow-up
 1. Possible B virus exposure – receiving treatment.
 - a. One week follow-up visit. The worker is interviewed for symptoms suggestive of an infection with B virus, compliance with treatment, and possible side effects to the medication. In addition, the wound is checked, an additional 42 tablets of valacyclovir is provided and the worker is given an appointment to return in a week.
 - b. Two week follow-up visit. The worker again is interviewed for symptoms suggestive of an infection with B virus, compliance with treatment, and possible side effects to the medication. The worker is given an appointment to return in another four weeks.
 - c. Six week follow-up visit. The worker is interviewed for symptoms suggestive of an infection.
 - d. The employee's serum may be tested for antibodies to B virus, if there are symptoms suggestive of an infection with B virus.
 2. Possible B virus exposure – treatment recommended but declined.
 - a. One week follow-up visit. The worker is interviewed for symptoms suggestive of an infection with B virus and the wound is checked.
 - b. Two and four week follow-up visit. The worker is again questioned for symptoms suggestive of infection with B virus and blood is obtained for serum storage.
 3. Possible retrovirus exposure.
 - a. The OMS guidelines for follow-up evaluations are outlined in the OMS Retrovirus Exposure procedure.

VIII. Record Keeping and Reporting

- A. The injury is recorded in the OMS Accident Reporting System and, if indicated, an OWCP claim form is issued. Details are provided in the OMS guidelines for Reporting Occupational Injuries and Illnesses.
- B. All injuries potentially involving NHP body fluids are reported to a safety specialist by the OMS healthcare provider at the time the injury is reported. The safety specialist interviews the employee, performs a work site assessment and offers appropriate safety advice to the employee and supervisor.
- C. The OMS lab coordinator maintains a log of B virus related laboratory test results. The following information is recorded in the log:
 1. The date the injury occurred and the date the sample was shipped for testing,

III-18. NONHUMAN PRIMATE BODY FLUID EXPOSURES

2. Name of the worker,
 3. The employee/worker's employer (e.g., IC, contractor),
 4. Location (e.g., building, room) at the time of the injury,
 5. Identification of the nonhuman primate,
 6. Name address and telephone number of the IC and facility veterinarian,
 7. The type of injury (e.g., bite, scratch), and
 8. Tests requested and results received for the nonhuman primate.
- D. All laboratory test results for the nonhuman primate are shared with the animal's IC veterinarian.

IX. Bibliography

- A. Holmes GP, Chapman LE, Stewart JA, Straus SE, and Hilliard JK. Guidelines for the Prevention and Treatment of B-Virus Infections in Exposed Persons. *CID* 1995;20:421-39.
- B. Cohen JI, Davenport DS, Stewart JA, Deichman S, Hilliard JK, Chapman LE. Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine Herpesvirus 1). *CID* 2002;35:1191-203.
- C. Huff JL, Barry PA. B-Virus (Cercopithecine Herpesvirus 1) Infections in Humans and Macaques: Potential for Zoonotic Disease. *Emerging Infect Dis* 2003;9:246-50.
- D. Jones, T.C., Mohr, U., and Hunt R.D. (Eds) *Nonhuman Primates I: Monographs on Pathology of Laboratory Animals Sponsored by the International Life Sciences Institute*. Springer-Verlag Berlin Heidelberg 1993.
- E. CDC. Seroconversion to Simian Immunodeficiency Virus in Two Laboratory Workers. *MMWR*. 1992;41:678-81.
- F. CDC. Anonymous Survey for Simian Immunodeficiency Virus Seropositivity in SIV-Laboratory Researchers - United States, 1992. *MMWR*. 1992;41:814-5.
- G. Khabbaz RF, Heneine W, George JR, et al. Brief Report: Infection of a Laboratory Worker with Simian Immunodeficiency Virus. *New Engl J of Med* 1994;330:172-7.
- H. Lerche NW, Switzer WM, Yee JL, Shanmugam V, Rosenthal AN, Chapman LE, Folks TM and Heneline W. Evidence of Infection with Simian Type D Retrovirus in Persons Occupationally Exposed to Nonhuman Primates. *J. Virol*. 2001;75:1783-9.
- I. Witvrouw M, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. *Antiviral Therapy* 9(2004):57-65.
- J. CDC B virus Homepage: <http://www.cdc.gov/herpesbvirus/>

Information and Specimens Requested following an Exposure to a NHP Body Fluid

| Injury involving a rhesus, cynomolgus, pig tail, stump tail or other macaque body fluid: | | | | | | | |
|---|---------------------|-------------------------------------|-------------------------------|----------|-----------------------|--------------------------------------|--|
| NHP Body Fluid | NHP Medical History | | NHP Physical Exam Findings | | | NHP Laboratory Testing | |
| | Known Infections | Last Test for B virus Result & Date | Oral | Genital | Ocular Conjunctivitis | B Virus Culture | Blood Testing for B Virus |
| | | | Vesicles, Ulcerations, Crusts | | | | |
| Blood | Provide | Provide | Provide* | Provide* | Provide* | Combine oral, ocular, genital | If not previously positive for B virus* |
| Saliva | Provide | Provide | Provide | Provide | Provide | One oral, combine ocular and genital | If not previously positive for B virus |
| Unknown | Provide | Provide | Provide* | Provide* | Provide* | Combine oral, ocular, genital | If not tested or previous test negative for B virus* |

* Only if the injury may have involved exposure to saliva or other mucous membrane fluid.

| Possible exposure to a body fluid from an African green monkey, baboon, sooty mangabey, or chimpanzee: | | | | | | | |
|---|---------------------|---------------------------|-------------------------------|---------|-----------------------|------------------------|------------------------------------|
| NHP Body Fluid | NHP Medical History | | NHP Physical Exam Findings | | | NHP Laboratory Testing | |
| | Known Infections | Last SIV Test Result Date | Oral | Genital | Ocular Conjunctivitis | SIV Culture | Blood Testing for SIV |
| | | | Vesicles, Ulcerations, Crusts | | | | |
| Blood | Provide | Provide | NA | NA | NA | NA | If not previously positive for SIV |
| Saliva | Provide | NA | NA | NA | NA | NA | NA |
| Unknown | Provide | NA | NA | NA | NA | NA | NA |

| Possible exposure to a body fluid from a marmoset, squirrel or owl monkey: | | | |
|---|---|----------------------------|------------------------|
| Body Fluid: | NHP Medical History, Known Infections, Contact with NHPs of Other Species | NHP Physical Exam Findings | NHP Laboratory Testing |
| Blood | Provide | NA | NA |
| Saliva | Provide | NA | NA |
| Unknown | Provide | NA | NA |

REPORT OF AN INJURY INVOLVING A NHP BODY FLUID

Employee

Name: _____ SSN: _____
Last First MI (Last 4)

Occupation: _____ Work Phone: _____

History

Date of report: _____ Time of report: _____
Date of injury: _____ Time of injury: _____

Location of injury (Bldg., Floor, Room): _____

Safety measures employed at time of exposure/injury: (check all that apply)

- Gloves, specify type: _____
- Eye protection
- Mask
- Other, specify: _____

Type of exposure:

- Skin exposure:
 - Skin intact
 - Skin disrupted
 - Mucous membrane exposure:
 - Eye(s), specify: Right Left Both
 - Nose
 - Mouth
 - Percutaneous injury:
 - Bite
 - Scratch
 - Puncture
- Describe instrument involved: _____
Location: _____
- Laceration
Describe instrument involved: _____
Location: _____

Type of NHP involved:

- Rhesus
 - Cynomolgus
 - Pig tail
 - Stump tail
- Other macaque, specify:
- | | | | |
|---|--|---|-------------------------------------|
| <input type="checkbox"/> African green monkey | <input type="checkbox"/> Baboon | <input type="checkbox"/> Sooty mangabey | <input type="checkbox"/> Chimpanzee |
| <input type="checkbox"/> Marmoset | <input type="checkbox"/> Squirrel monkey | <input type="checkbox"/> Owl monkey | <input type="checkbox"/> Unknown |

NHP body fluid possibly involved:

- Blood (consider SIV, if the NHP is a African green monkey, baboon, sooty mangabey, or chimpanzee)
- Saliva (consider B virus, if the NHP is a rhesus, cynomolgus, pig tail, stump tail or other macaque)
- Ocular fluid (consider B virus, if the NHP is a rhesus, cynomolgus, pig tail, stump tail or other macaque)
- Other, specify: _____

Circumstances of the injury, describe what the worker was doing at the moment the injury occurred:

First aid, worksite:

None
 Wound cleansed/irrigated
 Time elapsed from injury to initiation of first aid at work: _____
 Agent(s) utilized: _____
 Duration of first aid: _____

First aid, OMS:

None
 Wound cleansed/irrigated
 Time elapsed from injury to initiation of first aid at work: _____
 Agent(s) utilized: _____
 Duration of first aid: _____

Source

Responsible Veterinarian: _____
Work Phone: _____
NHP Identity: _____
Known infections (natural and experimental): _____

Physical exam findings suggestive of a herpetic infection (e.g., mucosal ulceration, crusting, etc.), only necessary if the NHP is a rhesus, cynomolgus, pig tail, stump tail or other macaque:

No
 Yes, explain: _____

Existing serologic studies and test dates:

| | Not previously tested | Test result/Test date |
|----------------------|--------------------------|-----------------------|
| B virus ¹ | <input type="checkbox"/> | _____ |
| SIV ² | <input type="checkbox"/> | _____ |
| Other, specify: | <input type="checkbox"/> | _____ |
| _____ | <input type="checkbox"/> | _____ |

¹ Only if the NHP is a rhesus, cynomolgus, pig tail, stump tail or other macaque

² Only if the NHP is an African green monkey, baboon, sooty mangabey, or chimpanzee

Last four SSN: _____ Employee initials: _____ Date: _____

NHP: Lab Studies Ordered

| | Check if ordered | Result/Date received |
|---|--------------------------|----------------------|
| B-Virus culture, buccal only | <input type="checkbox"/> | _____ |
| B-Virus culture, other than buccal only | <input type="checkbox"/> | _____ |
| Describe: _____ | | |
| Anti-B-virus | <input type="checkbox"/> | _____ |
| Anti-SIV | <input type="checkbox"/> | _____ |
| Other, explain: _____ | <input type="checkbox"/> | _____ |

Employee: Lab Studies Ordered

| | Check if ordered | Result/Date received |
|------------------------------|--------------------------|----------------------|
| Save serum | <input type="checkbox"/> | _____ |
| Wound BV culture, post-scrub | <input type="checkbox"/> | _____ |
| Other, explain: _____ | <input type="checkbox"/> | _____ |

Enrollment in Retrovirus Exposure Surveillance Program (RESP)

RESP is offered only to NIH employees who work with African green monkeys, baboons, sooty mangabeys or chimpanzees or intentionally work with HIV-1, HIV-2/SIV, or HTLV I/II.

Check appropriate choice:

- Previously enrolled
- Enrolled today, possible retrovirus exposure
 - SIV
 - Other retrovirus, explain: _____
- Enrolled today, retrovirus exposure not suspected
- Occupationally "indicated", but declined
- Occupationally "indicated", but not eligible (contract worker)
- Not occupationally "indicated"

Assessment

- Possible B-virus exposure
- Possible SIV exposure
- Possible exposure to another human pathogen, specify: _____
- No recognized exposure to a human pathogen

Treatment

- None indicated
- Valacyclovir 1 gm tid (500 mg tabs, 2 tid)
 - Time from injury to initiation _____
- Combivir 1 tab bid (150/300 mg tab, bid)
 - Time from injury to initiation _____
- Tenofovir 1 tab bid (300 mg tab, bid)
 - Time from injury to initiation _____
- Nelfinavir 1.25 gm bid (625 mg caps, 2 bid)
 - Time from injury to initiation _____
- Other, specify: _____
 - Time from injury to initiation _____
- Decision held pending results of source's and/or employee's lab studies

Last four SSN: _____ Employee initials: _____ Date: _____

Administrative Actions

- 2159 issued
- CA-1 issued
- Safety specialist notified

(Name): _____ Date/Time: _____ / _____

Medical Follow-Up (check all appropriate responses)

- None indicated
- Decision pending results of source's laboratory test results
- Possible B-virus exposure, valacyclovir taken
 - 1 week follow-up visit, date _____ (medications)
 - 2 week follow-up visit, date _____
 - 6 week follow-up visit, date _____
- Possible B-virus exposure, valacyclovir recommended, but declined
 - 1 week follow-up visit, date _____
 - 2 week follow-up visit, date _____
 - 4 week follow-up visit, date _____
- Possible SIV exposure, anti-retroviral therapy taken
 - 3 day follow-up visit, date _____
 - 2 week follow-up visit, date _____ (medications and related lab testing)
 - 4 week follow-up visit, date _____ (medication-related lab testing)
 - 6 week follow-up visit, date _____ (anti-SIV/HIV-2)
 - 3, 6, and 12 month follow-up visits (anti-SIV/HIV-2)
- Possible SIV exposure, anti-retroviral therapy recommended, but declined
 - 2 week follow-up visit, date _____
 - 6 week follow-up visit, date _____ (anti-SIV/HIV-2)
 - 3, 6, and 12 month follow-up visits (anti-SIV/HIV-2)
- Other, specify:

Comments

OMS RN: _____ OMS PA/MD: _____

Last four SSN: _____ Employee initials: _____ Date: _____

B Virus Backgrounder

Q: What is B virus?

A: B virus is a herpes virus. Old World nonhuman primates (NHPs) such as rhesus, cynomolgus, pig-tail and stump-tail NHPs are frequently infected with B virus. Infection with B virus produces a very mild disease in NHPs. Most infected NHPs have no obvious evidence that they are infected. Some NHPs may develop tiny blisters which quickly develop into small, shallow ulcers. The blisters and ulcers may occur in the mouth, face, lips, eyes, or genitals. Although the rash heals quickly, the virus remains in the NHP's involved nerves permanently. Later, the NHP may shed the virus in the same areas when it is "stressed". There usually is no obvious evidence that shedding is occurring.

Q: How is B virus passed from an infected monkey to a human?

A: For transmission to occur several things must happen. First, the NHP must have been infected with B virus. Second, if the injury involves a NHP fluid, the NHP must be currently shedding the virus. Third, the virus must be found in the NHP fluid or tissue involved in the injury. Finally, the NHP fluid or tissue must get through the worker's skin (for example by a puncture or laceration) or onto the worker's mucous membrane or non-intact skin. Each of these requirements must be met in order to transfer B virus to the worker.

Q: Who is at risk for infection with B-virus?

A: Those at risk include animal caretakers, laboratory staff, or anyone who has possible contact with Old World NHPs or their unfixed tissues. Persons whose immunity is weakened due to a medical condition or medical treatment may be at higher risk for infection. That said, the risk of being infected with B virus is probably very low. Thousands of persons have handled macaques since human infection with B virus infection was first reported in 1932. Yet, less than 30 cases of human infection have been documented.

Q: How can I protect myself from infection?

A: Proper work practices markedly reduce the chances of infection. When working with NHPs:

1. Exercise caution at all times. Remember NHPs are wild animals.
2. Wear appropriate personal protective equipment, as instructed.
3. Minimize direct handling of NHPs. Work with at least one other person when handling awake NHPs, if necessary.
4. Report all NHP blisters and ulcerations to a staff veterinarian.
5. If possibly exposed to oral, genital or ocular secretions or neural tissues from an Old

World NHP, immediately initiate first aid. Contaminated skin and wounds should be washed thoroughly with soap and water for 15 minutes. Contaminated eyes and mucous membranes should be irrigated with saline or water for 15 minutes. As soon as you have completed the first aid, notify your supervisor and report to the Occupational Medical Service (OMS) for further care. If OMS is closed, call the NIH operator (301-496-1211) and ask the operator to page the OMS physician immediately.

Q: What are the signs and symptoms of B virus infection in humans?

A: B-virus is characterized by a variety of signs and symptoms, which generally occur within one month of exposure. The early signs and symptoms can occur within hours to days of being infected with the virus. The following list describes early B virus infection symptoms. Note that there is no orderly sequence of events.

1. Fever and chills.
2. Flu-like symptoms including headache, fatigue, and muscle aches.
3. Itching, pain, numbness or loss of feeling at the injury site that increases toward the body.
4. Twenty to thirty percent of workers develop blisters or shallow open ulcers at or near the injury site.

If any of the above symptoms occur following an injury involving an Old World NHP, or equipment contaminated with their secretions or tissues, immediately call OMS.

OMS Contact Information

During business hours from 7:30 am to 5 pm, Monday to Friday, except federal holidays call the nearest OMS clinic:

OMS Bethesda, MD 301-496-4411,
OMS Frederick, MD 301-631-7233,
Baltimore, MD 443-740-2309, or
Hamilton, MT 406-375-9755.

When OMS is closed (weekdays from 5:00 pm to 7:30 am, weekends and federal holidays), call the NIH operator (301-496-1211) and ask to speak with the OMS on-call physician. Please allow for the two-hour time difference between the Eastern and Mountain time zones.

(B Virus Wallet Card)

-front-

Symptoms of B virus (*Macacine herpesvirus-1*) Infection

Very few people have been infected with B virus. However, if an infection does occur, it can be life-threatening. Prompt medical evaluation and treatment are important. Please read the following list of symptoms which may be related to a B virus infection.

1. Flu-like symptoms:
 - a. Fever and chills,
 - b. Muscle aches, or
 - c. Headache and fatigue.

2. At the injury site:
 - a. Itching or pain,
 - b. Tiny blisters or shallow ulcers, or
 - c. Numbness or loss of feeling.

-reverse-

Contact the Occupational Medical Service (OMS) if you have any questions about these symptoms.

If any of these symptoms occur within a month from the date of your injury, you should immediately contact OMS for an emergency evaluation. When OMS is closed (5:00 pm to 7:30 am, weekends and federal holidays), call the NIH operator (301-496-1211) and ask to speak with the OMS on-call physician. Give the operator your name and a phone number where you can be reached. An OMS physician will contact you within 15 minutes.

OMS Bethesda, MD 301-496-4411
OMS Frederick, MD 301-631-7233
Baltimore, MD 443-740-2309
Hamilton, MT 406-375-9755